Heightened health awareness, the expanding consumer base for incontinence products, as well as pandemic-induced rising enrolment in Medicaid, a critical safety net for a vast vulnerable population during economic downturns, continued to drive Rx/reimbursement incontinence spending in 2021. In July 2021, nearly 77 million Americans, or nearly one in four Americans, were enrolled in Medicaid, according to the Centres for Medicare & Medicaid Services. However, the growth of Rx/reimbursement inconti...

Euromonitor International’s Rx/Reimbursement adult incontinence in USA report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market – be they new product developments, distribution or pricing issues. Forecasts to 2026 illustrate how the market is set to change.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Rx/Reimbursement adult incontinence market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years’ experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.